Trial Profile
A Phase II, Open-Label Safety and Tolerability Study of an Renal Autologous Cell Therapy (REACT) in Patients With Type 2 Diabetes and Chronic Kidney Disease (REGEN-003)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2023
Price :
$35
*
At a glance
- Drugs Rilparencel (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors ProKidney
- 10 Jan 2023 According to a ProKidney media release, trial design were published in the Journal of Blood Purification.
- 10 Jan 2023 According to a ProKidney media release, early data from this trial were presented in the Journal of Blood Purification.
- 10 Jan 2023 Results published in the ProKidney Media Release.